Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Time to publication of oncology trials and why some trials are never published.

Chapman PB, Liu NJ, Zhou Q, Iasonos A, Hanley S, Bosl GJ, Spriggs DR.

PLoS One. 2017 Sep 21;12(9):e0184025. doi: 10.1371/journal.pone.0184025. eCollection 2017.

2.

Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.

Massey PR, Wang R, Prasad V, Bates SE, Fojo T.

Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.

3.

The fate of prospective spine studies registered on www.ClinicalTrials.gov.

Ohnmeiss DD.

Spine J. 2015 Mar 1;15(3):487-91. doi: 10.1016/j.spinee.2014.10.008. Epub 2014 Oct 12.

PMID:
25315132
4.

Factors associated with failure to publish large randomized trials presented at an oncology meeting.

Krzyzanowska MK, Pintilie M, Tannock IF.

JAMA. 2003 Jul 23;290(4):495-501.

PMID:
12876092
5.

Why are medical and health-related studies not being published? A systematic review of reasons given by investigators.

Song F, Loke Y, Hooper L.

PLoS One. 2014 Oct 15;9(10):e110418. doi: 10.1371/journal.pone.0110418. eCollection 2014. Review.

6.

Publication status of contemporary oncology randomised controlled trials worldwide.

Chen YP, Liu X, Lv JW, Li WF, Zhang Y, Guo Y, Lin AH, Sun Y, Mao YP, Ma J.

Eur J Cancer. 2016 Oct;66:17-25. doi: 10.1016/j.ejca.2016.06.010. Epub 2016 Aug 11.

PMID:
27522246
7.

Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials.

van den Bogert CA, Souverein PC, Brekelmans CT, Janssen SW, Koëter GH, Leufkens HG, Bouter LM.

PLoS One. 2016 Dec 14;11(12):e0167709. doi: 10.1371/journal.pone.0167709. eCollection 2016.

8.

Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.

Mitchell AP, Hirsch BR, Abernethy AP.

Trials. 2014 Mar 25;15:92. doi: 10.1186/1745-6215-15-92.

9.

Publication outcomes of phase II oncology clinical trials.

Hoeg RT, Lee JA, Mathiason MA, Rokkones K, Serck SL, Crampton KL, Emmel AE, Severson EA, Go RS.

Am J Clin Oncol. 2009 Jun;32(3):253-7. doi: 10.1097/COC.0b013e3181845544.

PMID:
19349853
10.

Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.

Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL Jr.

Clin Trials. 2010 Aug;7(4):312-21. doi: 10.1177/1740774510374973. Epub 2010 Jul 1.

11.

Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis.

Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM.

BMJ. 2012 Jan 3;344:d7292. doi: 10.1136/bmj.d7292.

12.

Updating Systematic Reviews.

Shojania KG, Sampson M, Ansari MT, Ji J, Garritty C, Rader T, Moher D.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Sep.

13.

Accrual to Trans-Tasman Radiation Oncology Group-sponsored trials 2010-2012.

Christie DR.

J Med Imaging Radiat Oncol. 2013 Aug;57(4):499-502. doi: 10.1111/1754-9485.12047. Epub 2013 Apr 7.

PMID:
23870351
14.

Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.

Schroen AT, Petroni GR, Wang H, Thielen MJ, Sargent D, Benedetti JK, Cronin WM, Wickerham DL, Wang XF, Gray R, Cohn WF, Slingluff CL, Djulbegovic B.

Clin Trials. 2011 Oct;8(5):591-600. doi: 10.1177/1740774511419683. Epub 2011 Aug 30.

15.

Delayed publication of clinical trials in cystic fibrosis.

Hurley MN, Prayle AP, Smyth AR.

J Cyst Fibros. 2012 Jan;11(1):14-7. doi: 10.1016/j.jcf.2011.08.004. Epub 2011 Sep 1.

16.

Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database.

Shepshelovich D, Goldvaser H, Wang L, Abdul Razak AR.

Invest New Drugs. 2018 Oct;36(5):933-938. doi: 10.1007/s10637-017-0549-6. Epub 2017 Dec 13. Review.

PMID:
29234946
17.

Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries.

Schmucker C, Schell LK, Portalupi S, Oeller P, Cabrera L, Bassler D, Schwarzer G, Scherer RW, Antes G, von Elm E, Meerpohl JJ; OPEN consortium.

PLoS One. 2014 Dec 23;9(12):e114023. doi: 10.1371/journal.pone.0114023. eCollection 2014.

18.

Timely and complete publication of economic evaluations alongside randomized controlled trials.

Thorn JC, Noble SM, Hollingworth W.

Pharmacoeconomics. 2013 Jan;31(1):77-85. doi: 10.1007/s40273-012-0004-7.

PMID:
23329594
19.

[Non-publication is common among phase 1, single-center, not prospectively registered, or early terminated clinical drug trials].

van den Bogert CA, Souverein PC, Brekelmans CTM, Janssen SWJ, Koëter GH, Leufkens HGM, Bouter LM.

Ned Tijdschr Geneeskd. 2017;161:D1498. Dutch.

PMID:
28659210
20.

Speed of Accrual Into Phase III Oncology Trials: A Comparison Across Geographic Locations.

Ruther NR, Mathiason MA, Wee SK, Emmel AE, Go RS.

Am J Clin Oncol. 2015 Dec;38(6):575-82. doi: 10.1097/01.coc.0000436087.69084.c6.

PMID:
24517955

Supplemental Content

Support Center